Samrotamab, also known as LCL100, represents a notable breakthrough in medical research. This innovative targeted antibody is currently in development evaluation and demonstrates impressive potential for combating https://mediajx.com/story27858122/samrotamab-a-hopeful-clonal-molecule-in-development